Scarica l'app Stockscreener
17.22
3.10%
-0.55
Dopo l'orario di chiusura:
17.71
0.49
+2.85%
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares - MarketBeat
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $121,672.60 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com Nigeria
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - MarketBeat
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 - Investing.com
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8%Still a Buy? - MarketBeat
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap UpHere's What Happened - MarketBeat
MapLight Therapeutics stock rises after accelerating clinical trial timelines By Investing.com - Investing.com Nigeria
MapLight Therapeutics stock rises after accelerating clinical trial timelines - Investing.com
MapLight Therapeutics accelerates timeline for Phase 2 trial results By Investing.com - Investing.com Nigeria
MapLight updates trial timelines and highlights CNS pipeline - TipRanks
MapLight Therapeutics accelerates timeline for Phase 2 trial results - Investing.com
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewswire Inc.
MapLight Therapeutics Expects Topline Results From Phase 2 Zephyr, Iris Trials in Q3 - marketscreener.com
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com Nigeria
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 7.9%Should You Sell? - MarketBeat
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to Hold Rating - Defense World
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):